Clinical trials: Malaria Transmission
Plasmodium Infection
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria…
- Trial name
- NCT05117567
- Testing
- Personal protection package
- Volunteers
- 5,868 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Pregnancy, Malaria
Safe Pregnancy by Infectious Disease Control
Malaria and sexually transmitted infections (STIs) are common in pregnant women in Africa and are important preventable causes of poor birth outcomes and maternal and infant mortality.
- Trial name
- NCT00489619
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 2,008 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Malaria
Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children
Intermittent preventive treatment (IPT) offers a way of preventing malaria infection without compromising the development of malaria immunity or encouraging drug resistance.
- Trial name
- NCT00561899
- Testing
- SP, amodiaquine, piperaquine, dihdroartemisinin, intermittent preventive treatment, Du-Cotecxin
- Where
- The Gambia
- Volunteers
- 1,295 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P.
- Trial name
- NCT01954264
- Testing
- Capillary blood sample, Data collection
- Where
- 3 sites in Burkina Faso, Senegal
- Volunteers
- 2,421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Malaria
Malaria Survey in Mbarara District, Uganda 2010
Malaria is one of the major public health problems in Sub-Saharan Africa. In response to this threat, Roll Back Malaria (RBM) has rolled back a strategy using ACT as first line therapy for malaria episode, a wide distribution of…
- Trial name
- NCT01062386
- Where
- Uganda
- Volunteers
- 2,320 people, healthy volunteers welcome
- Sponsor
- Epicentre
Malaria
Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Background: Malaria is a disease that is spread by mosquitoes. Researchers are looking for a vaccine that can prevent mosquitoes from transmitting malaria to people.
- Trial name
- NCT01867463
- Testing
- Pfs25-EPA/Alhydrogel, Euvax B, Menactra
- Where
- Mali
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Malaria
Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
The purpose of this study is to see if taking nevirapine (NVP) for HIV changes the way artemether/lumefantrine (AL) works in children who are co-infected with both HIV and malaria.
- Trial name
- NCT01728961
- Testing
- Artemether/Lumefantrine (AL)
- Where
- 3 sites in Malawi, Uganda
- Volunteers
- 19 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Plasmodium Falciparum Infection
Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults
Single site, double-blinded, randomized, placebo-controlled clinical trial of PfSPZ-CVac safety, tolerability, immunogenicity and efficacy against naturally occurring malaria in malaria-exposed Malian adults.
- Trial name
- NCT02996695
- Testing
- Artesunate, Chloroquine, PfSPZ (NF54) Challenge
- Where
- Mali
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Malaria
RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission
Reactive treatment of household contacts of a confirmed malaria case has been shown to reduce infection prevalence since the former as they are at an increased risk of infection.
- Trial name
- RHOST (NCT02878200)
- Testing
- dihydroartemisinin-piperaquine
- Where
- The Gambia
- Volunteers
- 2,236 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
Background: Malaria is a disease carried by mosquitoes in tropical countries around the world. It can cause symptoms like fever, body aches, and weakness.
- Trial name
- NCT05913973
- Testing
- Pvs230D1-EPA/Matrix-M
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea
Background: Half of the world s population is at risk of malaria. In 2015, there were 214 million cases of malaria and 438,000 deaths. A transmission-blocking vaccine (TBV) could help end the disease.
- Trial name
- NCT04969913
- Where
- 2 sites in United States, Guinea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Human Immunodeficiency Virus
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
In many areas of the world most severely affected by the HIV/AIDS pandemic, insect and water-borne diseases such as malaria and diarrheal disease are common causes of illness and death.
- Conditions
- HIV Infections, Human Immunodeficiency Virus, Malaria, Plasmodium Falciparum
- Trial name
- ITN (NCT00914225)
- Testing
- Bednets and Water Purification
- Where
- 2 sites in Kenya
- Volunteers
- 500 people
- Sponsor
- University of Washington
Malaria in Pregnancy, Adherence, Treatment
Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya
This multi-centre study will compare the acceptability, feasibility, cost and incremental cost-effectiveness of intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP) with or without azithromycin to the…
- Trial name
- NCT04160026
- Testing
- Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine, Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine, Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer
- Where
- Kenya
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Trial name
- CHMI-trans1 (NCT02836002)
- Testing
- Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose)
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, Falciparum
Malaria Transmission Studies in Mali
Background: Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person.
- Trial name
- NCT01829737
- Where
- United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study
In western Kenya the prevalence of malaria in <5 year olds has fallen from 70% in 1997 to 40% in 2008, where it has now stagnated. Innovative approaches are needed to continue towards elimination.
- Trial name
- IVERMAL (NCT02511353)
- Testing
- ivermectin, dihydroartemisinin-piperaquine
- Where
- Kenya
- Volunteers
- 141 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults
Background: Malaria is caused by small germs carried by mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells and reduces oxygen in the blood.
- Trial name
- NCT01988636
- Testing
- PfSPZ Vaccine
- Where
- Mali
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum, Anemia in Children
Comparing Chemoprevention Approaches for School-based Malaria Control
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent screening and treatment (IST) - students will receive treatment if they have a…
- Trial name
- NCT05244954
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine
- Where
- Malawi
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore